Carol Burt was appointed as Lead Director at RESMED INC.
“the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.”
RESMED INC — fact timeline
Source-grounded facts extracted from RESMED INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Ronald Taylor departed as Director at RESMED INC.
“On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026.”
RESMED INC reported the quarter ended March 31, 2026 results: revenue $1,431.4, net income $398.7, EPS $2.74.
“Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended March 31, 2026 March 31, 2025 % Change Constant Currency (A) Revenue $ 1,431.4 $ 1,291.7 11 % 8 % Gross margin 62.2 % 59.3 % 5 Non-GAAP gross margin (B) 62.8 % 59.9 % 5 Selling, general, and administrative expenses 285.7 245.3 16 11 Non-GAAP selling,”
Aaron Bloomer was appointed as Chief Financial Officer at RESMED INC.
“On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.”
Brett Sandercock departed as Chief Financial Officer at RESMED INC.
“On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.”
Christopher DelOrefice was appointed as Director at RESMED INC.
“On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024”
RESMED INC reported the quarter ended March 31, 2024 results: revenue $1.2 billion, EPS $2.04.
“he prior year period • Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis • Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew”
RESMED INC reported quarter ended December 31, 2023 results: revenue $1,162.8, net income $208.8, EPS $1.42.
“and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended December 31, 2023 December 31, 2022 % Change Constant Currency (A) Revenue $ 1,162.8 $ 1,033.7 12 % 11 % Gross margin 55.6 % 56.1 % (1 ) Non-GAAP gross margin (B) 56.9 % 56.8 % — Selling, general, and administrative expenses 222.2 211.7 5 4 Research and”
RESMED INC: Amended and restated bylaws to address universal proxy rules, proxy card color requirement, and other updates (effective 2023-11-17).
“On November 17, 2023, the Board of Directors (the “Board”) of ResMed Inc., a Delaware corporation (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended, the “Bylaws”).”
RESMED INC shareholders approved Approve, on an advisory basis, the frequency of future say-on-pay votes on an annual basis at the 2023-11-16 meeting.
“Item of business 4: Approve, on an advisory basis, the frequency of future say-on-pay votes. 101,600,575 463,611 948,607 1,033,631”
RESMED INC shareholders approved Approve, on an advisory basis, the compensation of our named executive officers at the 2023-11-16 meeting.
“Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement (“say-on-pay”). 84,318,661 19,649,791 77,972 7,126,855”
RESMED INC shareholders approved Ratify selection of KPMG LLP as independent registered public accounting firm for fiscal year ending June 30, 2024 at the 2023-11-16 meeting.
“Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024. 105,125,513 5,995,541 52,225”
RESMED INC shareholders approved Election of ten directors named below at the 2023-11-16 meeting.
“Item 5.07. Submission of Matters to a Vote of Security Holders. On November 16, 2023, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2024; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”); and (4) approved, the frequency for an advisory vote of future say-on-pay votes on an annual basis.”
Lucile Blaise changed role as senior vice president, strategy & business development at RESMED INC.
“Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.”
Robert Douglas retired as special advisor to the CEO at RESMED INC.
“On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.”
Robert Douglas changed role as special advisor to the CEO at RESMED INC.
“On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.”
RESMED INC reported financial results for the quarter ended September 30, 2023.
“On October 26, 2023, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended September 30, 2023.”
RESMED INC reported fiscal year ended June 30, 2023 results: revenue $4,223.0, net income $897.6, EPS $6.09.
“per share $ 1.56 $ 1.33 17 Non-GAAP diluted earnings per share (B) $ 1.60 $ 1.49 7 Twelve Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 4,223.0 $ 3,578.1 18 % 21 % Gross margin 55.8 % 56.6 % (1 ) Non-GAAP gross margin (B) 56.5 % 57.7 % (2 ) Selling, general, and administrative expenses 874.0 737.5 19 22 Research and”
RESMED INC reported the quarter ended June 30, 2023 results: revenue $1,122.1, net income $229.7, EPS $1.56.
“Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 1,122.1 $ 914.7 23 % 23 % Gross margin 55.0 % 57.1 % (4 ) Non-GAAP gross margin (B) 55.8 % 57.8 % (4 ) Selling, general, and administrative expenses 240.7 193.0 25 26 Research and”
RESMED INC reported the quarter ended March 31, 2023 results: revenue $1,116.9 million, EPS $1.58.
“ASX: RMD) today announced results for its quarter ended March 31, 2023. Third Quarter 2023 Highlights All comparisons are to the prior year period • Revenue increased by 29% to $1,116.9 million; up 31% on a constant currency basis • Gross margin contracted 150 bps to 55.3%; non-GAAP gross margin contracted 200 bps to 56.1% • Income from operations increased 28%;”
David Pendarvis departed as global general counsel, chief administrative officer, and secretary at RESMED INC.
“On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023.”
RESMED INC reported the quarter ended December 31, 2022 results: revenue $ 1,033.7, net income $ 224.9, EPS $ 1.53.
“Three Months Ended December 31, 2022 December 31, 2021 % Change Constant Currency (A) Revenue $ 1,033.7 $ 894.9 16 % 20 % Gross margin 56.1 % 56.4 % (1 ) Non-GAAP gross margin (B) 56.8 % 57.6 % (1 ) Selling, general, and administrative expenses 211.7 185.4 14 20 Research and development expenses 69.9 62.5 12 15 Income from operations 280.2 248.7 13 Non-GAAP income from operations (B) 305.5 267.7 14 Net income 224.9 201.8 11 Non-GAAP net income (B) 244.4 216.2 13 Diluted earnings per share $ 1.53 $ 1.37 12 Non-GAAP diluted earnings per share (B) $ 1.66 $ 1.47 13”
Dr. Peter C. Farrell was appointed as chair emeritus at RESMED INC.
“In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.”
Michael J. 'Mick' Farrell was appointed as chair of the board of directors at RESMED INC.
“On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors.”
RESMED INC shareholders approved Advisory vote on compensation of named executive officers (say-on-pay) at the 2022-11-16 meeting.
“On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,”
RESMED INC shareholders approved Ratification of selection of KPMG LLP as independent registered public accounting firm for fiscal year ending June 30, 2023 at the 2022-11-16 meeting.
“On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,”
RESMED INC shareholders approved Election of ten nominees to serve on the board of directors at the 2022-11-16 meeting.
“On November 16, 2022, at our annual meeting of stockholders, our stockholders (1) elected the ten nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2023; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”). For Against Abstain Broker Non-Votes Item of business 1: Elect the following seven directors, each to serve until our 2023 annual meeting and until their successors are elected and qualified: Carol Burt 112,920,252 1,611,838 653,168 4,934,277 Jan De Witte 114,414,039 549,367 221,852 4,934,277 Karen Drexler 112,325,192 2,592,899 267,167 4,934,277 Michael Farrell 114,166,629 811,588 207,041 4,934,277 Peter Farrell 110,955,680 3,892,880 336,698 4,934,277 Harjit Gill 113,995,558 965,687 224,013 4,934,277 John Hernandez 113,649,577 1,311,352 224,329 4,934,277 Richard Sulpizio 102,238,286 12,686,008 260,”
Robert Douglas changed role as Interim President, Sleep and Respiratory Care at RESMED INC.
“Concurrent with Ms. Blaise’s July 1, 2022 appointment, Robert Douglas will no longer serve as our interim president, sleep and respiratory care business.”
Lucile Blaise was appointed as President, Sleep and Respiratory Care at RESMED INC.
“On June 28, 2022, we announced that we are promoting Lucile Blaise, age 51, to serve as our president, sleep and respiratory care business.”
Rob Douglas was appointed as interim president – sleep and respiratory care business at RESMED INC.
“Robert (“Rob”) Douglas, our president and chief operating officer, has been appointed to serve as our interim president – sleep and respiratory care business.”
Jim Hollingshead resigned as president – sleep and respiratory care business at RESMED INC.
“On May 5, 2022, we announced that Jim Hollingshead resigned as our president – sleep and respiratory care business, effective as of May 5, 2022, to pursue an opportunity with a new employer.”
Rajwant Sodhi departed as president – Software-as-a-Service business at RESMED INC.
“On August 24, 2021, we determined that, effective August 25, Rajwant (“Raj”) Sodhi would cease serving as our president – Software-as-a-Service business.”
Bobby Ghoshal was appointed as president – Software-as-a-Service business at RESMED INC.
“Effective August 25, 2021, we promoted Bobby Ghoshal, age 53, to serve as our president – Software-as-a-Service business.”
Rajwant Sodhi departed as president – Software-as-a-Service business at RESMED INC.
“On August 24, 2021, we determined that, effective August 25, Rajwant (“Raj”) Sodhi would cease serving as our president – Software-as-a-Service business and will cease full-time employment with us on September 1, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.